Aclaris Therapeutics, Inc. (ACRS) 株式分析

企業概要

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on the discovery and development of novel molecule product candidates designed to treat immuno-inflammatory diseases within the United States. The company operates within the Healthcare sector, specifically in the Biotechnology industry, which is characterized by high research and development expenditures and significant regulatory hurdles prior to product commercialization. As of the latest available data, the company holds a market capitalization of $494.04M, generated annual revenue of $7.83M, and employs a workforce of 69 individuals. These financial metrics indicate that Aclaris Therapeutics maintains a relatively small market footprint compared to large-cap pharmaceutical peers, reflecting its status as a specialized entity in the early-to-mid stages of its pipeline development rather than a mature revenue generator. The substantial market cap relative to its modest revenue suggests that the market is pricing in significant future potential from its pipeline assets, particularly Bosakitug, rather than current cash flow performance.

財務健全性

The company reported a trailing twelve-month (TTM) revenue of $7.83M, accompanied by a net income of -$64,923,000 and an EBITDA of -$74,035,000. The significant disparity between the modest revenue figure and the substantial net loss reveals a cost structure dominated by high operating expenses, likely driven by clinical trial costs and R&D activities typical for clinical-stage biotechnology firms. Free cash flow stands at -$30,631,876, indicating that the company is burning through cash reserves to fund its operations and development programs, which limits its immediate financial flexibility without additional capital raises. All three margin metrics reflect this loss-making status: the gross margin is 0.0%, the operating margin is -1724.6%, and the profit margin is 0.0%, highlighting the aggressive spending required to advance clinical candidates. The balance sheet shows $90.75M in cash and cash equivalents against only $2.12M in debt, supported by a debt-to-equity ratio of 2.05, which presents a unique profile where cash holdings are high despite the leverage ratio suggesting otherwise, likely due to the capitalization structure of biotech firms. This liquidity position provides a runway for operations, though the operating leverage is negative. The current ratio of 3.36 indicates strong short-term liquidity, suggesting the company can easily meet its short-term obligations with its available assets. Return on Equity (ROE) is -50.2% and Return on Assets (ROA) is -24.3%, metrics that reveal management is currently deploying capital to generate losses rather than returns, which is standard for clinical-stage companies but signals a lack of immediate profitability.

バリュエーション評価

The valuation metrics present a complex picture typical of unprofitable growth companies: the P/E Ratio (TTM) is N/A due to losses, while the Forward P/E is listed as -5.44, a negative figure that implies earnings are expected to remain negative in the forward period. The Price to Book ratio stands at 4.77, indicating that the market values the company at a significant premium of nearly five times its net asset value, reflecting confidence in the intangible value of the clinical pipeline. The Price to Sales ratio is extremely high at 63.13, and the EV/EBITDA is -5.45, suggesting that traditional earnings-based valuation methods are ineffective and that investors are relying entirely on revenue multiples and pipeline potential. The stock trades between a 52-week high of $4.89 and a 52-week low of $1.05, with the current price position dependent on real-time market data not provided in the facts, but the wide range demonstrates significant volatility over the past year. The Beta of 0.68 suggests that the stock price exhibits lower volatility relative to the broader market, moving less aggressively than the general market index during periods of stability.

Growth & Income

Revenue growth year-over-year is -85.9%, while earnings growth year-over-year is N/A, indicating a contraction in top-line revenue rather than organic expansion at this specific point in time. Since earnings growth is not calculable due to the N/A status of earnings, it is impossible to determine if earnings are growing faster or slower than revenue, but the negative revenue growth suggests a reduction in sales or a specific reporting anomaly within the TTM period. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means the company reinvests its limited resources directly into research and development rather than distributing income to shareholders. This strategy of retaining earnings for growth is consistent with the clinical-stage nature of the business, where capital preservation and pipeline advancement are prioritized over income distribution. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, positioning the asset strictly as a speculative growth play dependent on future product approvals.